Compare TechnipFMC plc Ordinary Share (FTI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TechnipFMC plc Ordinary Share vs Organon & Co. Common Stock — how do they compare? TechnipFMC plc Ordinary Share trades at $69.36 (market cap $27.73B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: TechnipFMC plc Ordinary Share is far larger — about 7.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| FTI | OGN | |
|---|---|---|
Market Cap | $27.73B | $3.62B |
Volume | 2,487,618 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $80.08 | $13.81 |
52-Week Low | $35.57 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $27.98B | $11.04B |
Dividend Yield | 0.28% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTI trades at $70.72, up 1.39% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 36.04% ROE and 11.28% net margin. Recent Petrobras contract wins and strategic hires strengthen its subsea and consulting capabilities. Analyst consensus remains bullish with a $80.50 price target representing 14% upside potential.
FTI presents a compelling growth story with consistent earnings outperformance and strategic expansion, though technical indicators suggest near-term consolidation. The primary risk involves execution of recent contracts and maintaining profitability amid rising expenses. With zero sell ratings and institutional accumulation, the stock offers upside potential for investors comfortable with energy sector volatility.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TechnipFMC plc Ordinary Share
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
